Outlook Therapeutics, Inc. (OTLK)
| Market Cap | 255.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.77M |
| Shares Out | 225.94M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 173,221 |
| Open | 1.11 |
| Previous Close | 1.11 |
| Day's Range | 1.10 - 1.14 |
| 52-Week Range | 0.68 - 3.27 |
| Beta | 0.84 |
| Analysts | Buy |
| Price Target | 7.06 (+524.8%) |
| Earnings Date | Aug 12, 2022 |
About OTLK
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for OTLK stock is "Buy." The 12-month stock price forecast is 7.06, which is an increase of 524.78% from the latest price.
News
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note
ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic form...
4 Hot Penny Stocks To Watch After Big June 2022 News
Penny stocks to watch right now. The post 4 Hot Penny Stocks To Watch After Big June 2022 News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010
ISELIN, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic form...
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment fo...
ISELIN, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formu...
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference
ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formu...
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update
ISELIN, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formu...
Outlook Therapeutics to Participate in Retina World Congress 2022
ISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formu...
Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight
Live moderated video webcast on Wednesday, May 11th at 1:00 PM ET Live moderated video webcast on Wednesday, May 11th at 1:00 PM ET
BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics
SINGAPORE and ISELIN, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ...
Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit
ISELIN, N.J., April 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bev...
Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a...
ISELIN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bev...
Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President ...
ISELIN, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bev...
Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress
Pivotal Phase 3 data from the NORSE TWO registration trial to be presented by Lawrence Lee, MD, MBBS, FRANZCO, FRACS Pivotal Phase 3 data from the NORSE TWO registration trial to be presented by Lawrenc...
Biotech Penny Stocks To Buy For Under $5 As Russia Ukraine Conflict Heats Up
Biotech penny stocks to watch as Ukraine-Russia conflict builds steam. The post Biotech Penny Stocks To Buy For Under $5 As Russia Ukraine Conflict Heats Up appeared first on Penny Stocks to Buy, Picks,...
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update
ISELIN, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of beva...
Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Live video webcast presentation on Friday, February 18th at 10:40 AM ET Live video webcast presentation on Friday, February 18th at 10:40 AM ET
Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations
ISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of beva...
3 Top Penny Stocks To Buy For Under $5 Today
Are these on your list of penny stocks to watch right now? The post 3 Top Penny Stocks To Buy For Under $5 Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Outlook Therapeutics Provides a Corporate Update and Business Outlook
ISELIN, N.J., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of beva...
4 Best Penny Stocks To Buy Now According To Top Wall Street Analysts
4 penny stocks to buy right now according to top Wall Street analysts. The post 4 Best Penny Stocks To Buy Now According To Top Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News an...
Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
Live video webcast presentation on Tuesday, January 25th at 3:00 PM ET Live video webcast presentation on Tuesday, January 25th at 3:00 PM ET
Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference
ISELIN, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of beva...
Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update
ISELIN, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bev...
Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT An...
Francesco Bandello, MD, FEBO, will present Phase 3 pivotal safety and efficacy data from the NORSE TWO registration trial Francesco Bandello, MD, FEBO, will present Phase 3 pivotal safety and efficacy d...
Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress
Suber Huang, MD, MBA, FASRS will present data from the Phase 3 pivotal NORSE TWO registration trial Suber Huang, MD, MBA, FASRS will present data from the Phase 3 pivotal NORSE TWO registration trial